Pacific Edge eyes final US milestone within year

Pacific Edge eyes final US milestone within year
Gavin Evans
By Gavin Evans Aug 1 (BusinessDesk) - Pacific Edge says it may achieve the key third element for reimbursement by private and public US health insurers for its Cxbladder cancer diagnostic tests within a year. The firm has already been granted a national price for its tests and two of its products have been granted national product codes for the US. Studies of Cxbladder published in European Urology and the New Zealand Medical Journal this year, and the products’ inclusion this month in the US National Comprehensive Cancer Network Guide...

More Services

Creative solutions needed to keep NZ workers
Economy

Creative solutions needed to keep NZ workers

Robert Walters sees talent migration potentially getting worse in 2025.

‘Battle-hardened’ Trade Window eyes growth
Markets

‘Battle-hardened’ Trade Window eyes growth

The customs software minnow has weathered the storm. What next?

Pattrick Smellie 21 Nov 2024
Crimson big enough for ASX IPO: Beaton
Finance

Crimson big enough for ASX IPO: Beaton

A US market listing at a greater scale looks more likely.

Pattrick Smellie 06 Nov 2024
CoreLogic data suggests property market floor is nigh
Property

CoreLogic data suggests property market floor is nigh

Broad economic trends underpin the latest figures, CoreLogic's economist says.